What's on this Page
Fluocinonide Brand Names
Fluovix | Fluovix Plus | Lidex | Lidex -E | Vanos
What is Fluocinonide
Fluocinonide is a synthetic, high-potency, fluorinated topical corticosteroid. The drug is used for symptomatic treatment of moderate to severe corticosteroid-responsive dermatoses characterized by inflammation and/or pruritus, such as seborrheic dermatitis, atopic dermatitis, and psoriasis.
The high potency of fluocinonide is advantageous for treating affected areas with thicker skin such as the palms and soles.
Unlike non-fluorinated corticosteroids such as hydrocortisone, fluocinonide application should be avoided, if possible, on areas of thinner skin, such as the face and intertriginous areas, because of potential toxicities inherent in fluorinated compounds.
Fluocinonide was first approved by the FDA in 1971.
Indications
- alopecia
- atopic dermatitis
- contact dermatitis
- cutaneous T-cell lymphoma (CTCL)
- dermatitis
- discoid lupus erythematosus
- eczema
- exfoliative dermatitis
- granuloma annulare
- keloids
- lichen planus
- lichen simplex
- lichen striatus
- mycosis fungoides
- necrobiosis lipoidica diabeticorum
- pemphigus
- pityriasis rosea
- pompholyx
- prurigo
- pruritus
- psoriasis
- Rhus dermatitis
- sarcoidosis
- seborrheic dermatitis
- urticaria
Side Effects
- acneiform rash
- adrenocortical insufficiency
- cataracts
- contact dermatitis
- Cushing’s syndrome
- erythema
- folliculitis
- glycosuria
- growth inhibition
- headache
- hyperglycemia
- hypertension
- hypertrichosis
- hypothalamic-pituitary-adrenal (HPA) suppression
- impaired wound healing
- increased intracranial pressure
- infection
- maculopapular rash
- miliaria
- ocular hypertension
- papilledema
- pruritus
- pseudotumor cerebri
- purpura
- skin atrophy
- skin hypopigmentation
- skin irritation
- skin ulcer
- striae
- telangiectasia
- tolerance
- visual impairment
- withdrawal
- xerosis
Monitoring Parameters
- laboratory monitoring not necessary
Contraindications
- acne rosacea
- acne vulgaris
- breast-feeding
- cataracts
- children
- corticosteroid hypersensitivity
- Cushing’s syndrome
- diabetes mellitus
- fungal infection
- geriatric
- glaucoma
- growth inhibition
- herpes infection
- hypothalamic-pituitary-adrenal (HPA) suppression
- increased intracranial pressure
- infants
- infection
- measles
- neonates
- occlusive dressing
- ocular exposure
- ophthalmic administration
- perioral dermatitis
- peripheral vascular disease
- pregnancy
- skin abrasion
- skin atrophy
- tuberculosis
- varicella
- viral infection
Interactions
- Metyrapone
Metyrapone: (Major) Medications which affect pituitary or adrenocortical function, including all corticosteroid therapy, should be discontinued prior to and during testing with metyrapone. Patients taking inadvertent doses of corticosteroids on the test day may exhibit abnormally high basal plasma cortisol levels and a decreased response to the test. Although systemic absorption of topical corticosteroids is minimal, temporary discontinuation of these products should be considered if possible to reduce the potential for interference with the test results.
